Xbrane Biopharma AB (publ) (STO:XBRANE)

R1 RCM Revenue

Xbrane Biopharma AB had revenue of 93.24M SEK in the quarter ending March 31, 2025, with 562.90% growth. This brings the company's revenue in the last twelve months to 277.89M, up 45.52% year-over-year. In the year 2024, Xbrane Biopharma AB had annual revenue of 198.72M, down -16.76%.

• Revenue (ttm): 277.89M
• Revenue Growth: +45.52%
• P/S Ratio: 1.49
• Revenue / Employee: 4.34M
• Employees: 65
• Market Cap: 413.08M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	198.72M	-40.01M	-16.76%
Dec 31, 2023	238.73M	181.11M	314.33%
Dec 31, 2022	57.62M	46.91M	438.03%
Dec 31, 2021	10.71M	-	-
Dec 31, 2020	-	-	-